Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...
Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by...
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by...
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by...
Company increases European customer-supplier relationships by 200% this yearBOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Labviva, the leading AI-powered procurement...
Company increases European customer-supplier relationships by 200% this yearBOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Labviva, the leading AI-powered procurement...
Company increases European customer-supplier relationships by 200% this yearBOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Labviva, the leading AI-powered procurement...
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse...
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse...
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse...
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks...
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks...
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks...
Fort Lee, NJ, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused...
Fort Lee, NJ, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused...
Fort Lee, NJ, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused...